What You Should Know:
– Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis announced the appointment of Dr. Robert “Bob” Pelberg as its new Senior Vice President of Medical Affairs.
– Dr. Pelberg, a highly accomplished cardiologist and nationally recognized expert in cardiovascular computed tomography angiography (CCTA), brings decades of clinical experience and a deep understanding of advanced imaging technologies and clinical research to Elucid.
In his new role, Dr. Pelberg will be instrumental in shaping and executing the company’s clinical and research strategies, as well as leading clinical operations quality efforts to ensure the highest clinical quality and regulatory standards.
A Pivotal Appointment for Elucid’s Growth and Innovation
Dr. Pelberg’s hiring comes at a crucial time for Elucid as the company accelerates both its clinical research strategy and the commercial growth of its flagship product, PlaqueIQTM image analysis software. PlaqueIQ is distinguished as the first and only FDA-cleared, non-invasive plaque analysis based on objective histology, rather than subjective CCTA visual estimates. This software quantifies and classifies plaque morphology based on ground-truth histology, considered the gold standard for plaque characterization. It is designed to help physicians prioritize and personalize treatment based on actual disease, moving beyond population-based risk assessments.
